Treatment of intermittent claudication with pentoxifylline and cilostazol

American Journal of Health-System Pharmacy

Volumn 58, Issue 6, 2001, Pages 485-493

  Tjon, J A ^a   Reimann, L E ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cilostazol; Clinical studies; Costs; Dosage; Drug comparisons; Drug interactions; Hemorrheologic agents; Intermittent claudication; Pentoxifylline; Peripheral diseases; Pharmacokinetics; Toxicity; Vasodilating agents

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; MILRINONE; NEFAZODONE; OMEPRAZOLE; PENTOXIFYLLINE; PHOSPHODIESTERASE; PIPERANOMETOZINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; QUINIDINE; TISSUE PLASMINOGEN ACTIVATOR;

BLEEDING; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG COST; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DYSPEPSIA; EDEMA; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; INTERMITTENT CLAUDICATION; LIFESTYLE; MUSCLE BLOOD FLOW; NAUSEA; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; VERTIGO;

EID: 0035869052     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/58.6.485     Document Type: Review

References (46)

1. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease
2. Pentoxifylline and intermittent claudication: Review of clinical trials and cost effectiveness analyses
3. Intermittent claudication: The natural history
4. Progressive intermittent claudication is associated with impaired fibrinolysis
5. Physical exertion induces thrombin formation and fibrin degradation in patients with peripheral atherosclerosis
6. Cross-linked fibrin degradation products, progression of peripheral artery disease, and risk of coronary heart disease
7. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral artery disease and the normal population in the Edinburgh Artery Study
8. Smoking, hemorheologic factors, and progression of peripheral arterial disease in patients with claudication
9. Intermittent claudication and risk of cardiovascular events
10. Intermittent claudication in older patients
11. The evidence for exercise-induced inflammation in intermittent claudication: Should we encourage patients to stop walking?
12. Exercise-induced neutrophil activation in claudicants: A physiological or pathological response to exhaustive exercise?
13. Exercise training for intermittent claudication: Does it adversely affect biochemical markers of the exercise-induced inflammatory response?
14. The effect of cigarette smoking status on six-minute walk distance in patients with intermittent claudication
15. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: A meta analysis
16. Role of systolic blood pressure and plasma triglycerides in diabetic peripheral arterial disease: The Edinburgh Artery Study
17. Intermittent claudication. Conservative treatment, endovascular repair, or open surgery for femoropopliteal disease
18. The use of angioplasty, bypass surgery and amputation in the management of peripheral vascular disease
19. Management of peripheral arterial disease
20. Treatment of claudication with dipyridamole and aspirin
21. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease: A prospective, double-blind arteriographically controlled trial
22. Antithrombotic therapy in peripheral arterial occlusive disease
23. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
24. Cilostazol has beneficial effects in treatment of intermittent claudication
25. Pentoxifylline: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy
26. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
27. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure
28. Otsuka Pletal approved with severe heart failure contraindication
29. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty
30. Antiplatelet treatment with cilostazol after stent implantation
31. Pharmacokinetics of multiple-dose oral cilostazol in middle-age and elderly men and women
32. Pentoxifylline for intermittent claudication: A critical review
33. Does pentoxifylline prolong the walking distance in exercised pentoxifyl-claudicants? A placebo-controlled double-blind trial
34. Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients
35. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease
36. Trental 400 in the treatment of intermittent claudication: Results of long-term, placebo-controlled administration
37. Placebo controlled double blind study with pentoxifylline of walking performance in patients with intermittent claudication
38. The effects of pentoxifylline on patients with intermittent claudication
39. Management of intermittent claudication with pentoxifylline: Meta-analysis of randomized, controlled trials
40. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease
41. A comparison of cilostazol and pentoxifylline for treating intermittent claudication
42. Cilostazol for intermittent claudication